Shree Ganesh Remedies Ltd
Shree Ganesh Remedies Q3 FY26: Revenue ₹21.11 Cr, PAT ₹3.10 Cr
Q3 FY26 investor presentation: what the company reported on revenue, margins and capex.
- Revenue
- ₹21Cr
- −22% YoY
- Net profit
- ₹3Cr
- −42.9% YoY
- Margin
- 31.88%
- −4.8 pp YoY
Guidance rank: #84 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
Based on Shree Ganesh Remedies Ltd's Q3 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q3FY26 Revenue from Operations: ₹21.11 Cr - Q3FY25 Revenue from Operations: ₹27.05 Cr - Year-on-Year (YoY) change in Q3FY26 revenue: -22% - Management states Q3FY26 impact due to shipment delays (~10-12% deferment), challenging demand in Europe, and price competition. Q3FY26 EBITDA: ₹6.73 Cr, down 32% YoY - Q3FY26 Operating Margin (EBITDA %): 31.9%, down 471 bps YoY - Q3FY26 Profit After Tax (PAT): ₹3.10 Cr, down 43% YoY - Explicit margin outlook: - Mana
From Shree Ganesh Remedies Ltd's Q3 FY26 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Q3FY26 Revenue from Operations: ₹21.11 Cr
- Q3FY25 Revenue from Operations: ₹27.05 Cr
- Year-on-Year (YoY) change in Q3FY26 revenue: -22%
- Management states Q3FY26 impact due to shipment delays (~10-12% deferment), challenging demand in Europe, and price competition.
- Revenue recognition deferred mostly to Q4FY26.
- FY26 termed a "year of consolidation" with focus on execution and capability-building over aggressive growth.
2 more points from Shree Ganesh Remedies Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Shree Ganesh Remedies Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Ankleshwar Site:
- Block 8 completed Capex in FY25.
- Block 7 Capex projected at ~₹20 Crores; ₹15 Crores outlay planned in FY26.
- Block 7 commissioning expected H1FY27.
- New Pilot Plant commissioned & operational (Q4FY26 automation & flow chemistries implementation planned).
- Dahej Land Acquisition:
- 40,554 sq m acquired in 2022; ₹11 Crores spent on land acquisition.
- Construction of common infrastructure and warehousing underway.
- Expansion to be phased; multiple projects evaluated (customer details under NDA).
- R&D Infrastructure:
- Overall Focus:
2 more points from Shree Ganesh Remedies Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Shree Ganesh Remedies Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Shree Ganesh Remedies Ltd said on order book & pipeline — free account, 30 seconds.
Shree Ganesh Remedies Ltd — Quarterly revenue & net profit
Shree Ganesh Remedies Ltd Q3 FY26 results — key figures
| ₹ Cr | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 21 | 27 | -22% | 30 | -30.4% |
| Operating profit (EBITDA) | 7 | 10 | -32.1% | 10 | -30% |
| Operating margin | 31.88% | 36.64% | -4.8 pp | 31.73% | +0.1 pp |
| Profit before tax | 4 | 8 | -47.2% | 7 | -40.7% |
| Net profit (PAT) | 3 | 5 | -42.9% | 5 | -37.5% |
| EPS (₹) | 2.41 | 4.23 | -43% | 3.86 | -37.6% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹33 Cr, net profit ₹6 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Shree Ganesh Rem's management said in earlier quarters
- Q1 FY27 earnings call analysis →
- Q1 FY26 earnings call analysis →
- Q3 FY25 earnings call analysis →
- Q2 FY25 earnings call →
Earlier calls (1)
Others in Pharmaceuticals & Biotechnology this season
- Natural Capsules (Q3 FY26)
Q3FY26 revenue from operations: ₹37.75 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q3 FY26 investor presentation — and how it ranks
- Wanbury (Q3 FY26)
Q3FY26 Revenue from Operations: ₹162.45 Crore . Key investor presentation takeaways from Wanbury Ltd's Q3 FY26 investor presentation — and how it ranks against
- Gujarat Themis Biosyn (Q3 FY26)
43.37 crore, up 9.74% YoY from Rs. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q3 FY26 investor presentation — and how it ranks against
- Balaxi Pharma (Q3 FY26)
Q3 FY26 revenue: ₹72.54 crore, down marginally by 1% YoY from ₹73.29 crore in Q3 FY25 (Page 19). Key investor presentation takeaways from Balaxi Pharma's Q3 FY2
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Shree Ganesh Remedies Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Shree Ganesh Remedies Ltd Q3 FY26 results?
Q3FY26 Revenue from Operations: ₹21.11 Cr - Q3FY25 Revenue from Operations: ₹27.05 Cr - Year-on-Year (YoY) change in Q3FY26 revenue: -22% - Management states Q3FY26 impact due to shipment delays (~10-12% deferment), challenging demand in Europe, and price competition. Q3FY26 EBITDA: ₹6.73 Cr, down 32% YoY - Q3FY26 Operating Margin (EBITDA %): 31.9%, down 471 bps YoY - Q3FY26 Profit After Tax (PAT): ₹3.10 Cr, down 43% YoY - Explicit margin outlook: - Mana
What is Shree Ganesh Remedies Ltd share price analysis?
Shree Ganesh Remedies Ltd currently shows a neutral. The stock trades at a P/E of 58.0 with a market cap of ₹896 Cr. Investors should review the full earnings analysis for detailed insights.
Is Shree Ganesh Remedies Ltd planning capital expenditure?
Ankleshwar Site: - Block 8 completed Capex in FY25.
Keep Shree Ganesh Remedies Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.